Aviceda Therapeutics, a Cambridge, MA-based private, clinical-stage biotech company focused on developing new immunomodulators, raised $207.5M in Series C financing.
The round was led by Omega Funds and TCGX, with participation from Enavate Sciences and Jeito Capital, alongside Longitude Capital, Blue Owl Healthcare Opportunities, and other investment firms.
pivotal Phase 3 clinical trial for AVD-104 in geographic atrophy (GA), a vision-threatening condition secondary to advanced age-related macular degeneration, and the expansion into other ophthalmic indications.
Aviceda is a private, clinical-stage biotechnology company developing a proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform and a clinical-stage ophthalmic candidate, AVD-104, for the treatment of geographic atrophy secondary to age-related macular degeneration.
Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including immunology, fibrosis, oncology, and neurology.
In connection with the Series C financing, Bernard Davitian of Omega Funds and Chen Yu, M.D., M.B.A., of TCGX have joined Aviceda’s Board of Directors. Evelyn Harrison, M.B.A., former Chief Operating Officer of Iveric Bio (part of Astellas Pharma Inc.) has also joined as an independent director, bringing valuable expertise in advancing novel therapies through late-stage clinical development and commercialization. In addition, Sara Nayeem, M.D. of Enavate Sciences and Rafaèle Tordjman, M.D. Ph.D. of Jeito Capital are appointed Board Observers.
